OKYO Pharma Announces Chairman and Founder Acquires Shares

OKYO Pharma (NASDAQ: OKYO) announced on Dec 15, 2025 that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 24,551 ordinary shares on NASDAQ.

Rhea-AI Summary

OKYO Pharma (NASDAQ: OKYO) announced on Dec 15, 2025 that Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest, acquired 24,551 ordinary shares on NASDAQ.

After the purchase, the Chairman's total holding increased to 10,516,297 shares. OKYO is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition currently without an FDA-approved therapy.

Positive

• Insider purchase of 24,551 shares on Dec 15, 2025
• Chairman stake totals 10,516,297 shares after the transaction

Negative

• None.

Argus Dec 15 session

-8.25% close to close Open Argus

Details

News Market Reaction – OKYO

On Dec 15, the day this news came out, OKYO closed 8.25% below the previous close.

Data tracked by StockTitan Argus for the Dec 15 session.

Market Context

On Dec 15, the day this news came out, the stock closed 8.3% below the previous close. A negative re...

Analysis

On Dec 15, the day this news came out, the stock closed 8.3% below the previous close. A negative reaction despite additional insider buying would fit the mixed pattern seen after prior acquisition-tagged updates, where one event saw a -5.77% move. The chairman’s growing stake to 10,516,297 shares underscores continued insider exposure, but price responses have not been uniformly positive. Investors may also factor in broader biotech volatility and the early-stage nature of urcosimod’s development.

Key Figures

Shares acquired: 24,551 shares Chairman holding: 10,516,297 shares Shares outstanding: 37,610,676 ordinary shares +5 more

Shares acquired

24,551 shares

Panetta Partners purchase disclosed Dec 15, 2025

Chairman holding

10,516,297 shares

Total beneficial holding after latest purchase

Shares outstanding

37,610,676 ordinary shares

As of July 3, 2025 per Form 20-F/A

Phase 2 sample size

18 patients

Neuropathic corneal pain Phase 2 trial

Planned trial size

120 patients

Planned multi-center clinical trial for urcosimod

Prior insider buy

82,018 shares

Purchase on November 21, 2025

Prior insider buy

27,051 shares

Purchase on December 3, 2025

Earlier 2025 insider buy

210,000 shares

Purchase announced October 16, 2025

Historical Context

5 past events · Latest: Dec 11

5 events

1. Dec 11

   Clinical data update

   24h Move

   +6.9%

   Phase 2 corneal nerve imaging data showed directionally favorable outcomes.

2. Dec 03

   Insider share purchase

   24h Move

   -5.8%

   Chairman-related entity acquired 27,051 shares, lifting holdings to 10.49M.

3. Nov 21

   Insider share purchase

   24h Move

   +11.0%

   Chairman-related entity bought 82,018 shares, increasing stake to 10.46M.

4. Nov 18

   Conference presentation

   24h Move

   -0.7%

   CEO presentation at OIS XV highlighting urcosimod and Phase 2 results.

5. Oct 29

   Conference appearance

   24h Move

   +6.7%

   BIO-Europe presentation on urcosimod Phase 2 data and development plans.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neuropathic corneal pain, fda-approved therapy

2 terms

neuropathic corneal pain medical

"developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition..."

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

fda-approved therapy regulatory

"nerve-related pain but without an FDA-approved therapy, today announces it has been..."

A FDA-approved therapy is a medical treatment that the U.S. Food and Drug Administration has reviewed and authorized for sale after assessing its safety and effectiveness. For investors, approval is like a major safety inspection passed and a license to sell broadly: it lowers regulatory risk, can unlock insurance payments and wider markets, and often increases a product’s commercial value and credibility.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON and NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, today announces it has been informed that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman, has a beneficial interest, has acquired 24,551 of the Company’s ordinary shares on NASDAQ, bringing his total holding to 10,516,297 shares.

About Urcosimod (Formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating ocular diseases. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to potentially enhance the efficacy of urcosimod within the ocular environment. Urcosimod showed clear statistical significance in multiple endpoints in a 240-patient completed Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and just completed a randomized, placebo-controlled, double-masked Phase 2 trial of urcosimod to treat neuropathic corneal pain.

About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain and dry eye disease, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. A Phase 2 trial of urcosimod to treat neuropathic corneal pain patients was just completed by OKYO.

For further information, please visit www.okyopharma.com.

Inquiries:

Business Development & Investor Relations

Paul Spencer

+44 (0)20 7495 2379

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many OKYO (NASDAQ: OKYO) shares did the Chairman acquire on Dec 15, 2025?

Panetta Partners acquired 24,551 ordinary shares on Dec 15, 2025.

What is Gabriele Cerrone's total holding in OKYO after the Dec 15, 2025 purchase?

His total holding is reported as 10,516,297 shares after the transaction.

Who made the OKYO share purchase reported on Dec 15, 2025?

The buyer was Panetta Partners Limited, an entity in which Executive Chairman Gabriele Cerrone has a beneficial interest.

Does the Dec 15, 2025 insider purchase change OKYO's development of urcosimod for NCP?

The announcement reports an insider share acquisition and does not state any change to urcosimod development or program timelines.

Where was OKYO's Dec 15, 2025 insider purchase disclosed?

The company announced the transaction publicly on Dec 15, 2025; investors should monitor required SEC filings for further details.